GSK plc (GSK) - Total Assets
Based on the latest financial reports, GSK plc (GSK) holds total assets worth GBX61.74 Billion GBX (≈ $7.51 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see GSK cash flow metrics for how efficiently the company converts equity into cash flow.
GSK plc - Total Assets Trend (1986–2025)
This chart illustrates how GSK plc's total assets have evolved over time, based on quarterly financial data. See GSK plc (GSK) share price today for real-time trading data and today's change.
GSK plc - Asset Composition Analysis
Current Asset Composition (December 2025)
GSK plc's total assets of GBX61.74 Billion consist of 28.7% current assets and 71.4% non-current assets. Explore working capital position of GSK plc to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 5.2% |
| Accounts Receivable | GBX6.58 Billion | 10.8% |
| Inventory | GBX5.92 Billion | 9.7% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX16.75 Billion | 27.4% |
| Goodwill | GBX7.02 Billion | 11.5% |
Asset Composition Trend (1986–2025)
This chart illustrates how GSK plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GSK plc's current assets represent 28.7% of total assets in 2025, a decrease from 67.7% in 1986.
- Cash Position: Cash and equivalents constituted 5.2% of total assets in 2025, up from 1.9% in 1986.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 38.0% of total assets, an increase from 0.0% in 1986.
- Asset Diversification: The largest asset category is intangible assets at 27.4% of total assets.
GSK plc Competitors by Total Assets
Key competitors of GSK plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
Roche Holding AG
SW:ROP
|
Switzerland | CHF100.70 Billion |
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX116.43 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥12.85 Billion |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357
|
China | CN¥2.89 Billion |
GSK plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.82 | 0.87 | 0.81 |
| Quick Ratio | 0.52 | 0.57 | 0.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX-3.98 Billion | GBX-2.71 Billion | GBX-4.16 Billion |
GSK plc - Advanced Valuation Insights
This section examines the relationship between GSK plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.28 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 2.8% |
| Total Assets | GBX61.12 Billion |
| Market Capitalization | $853.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values GSK plc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: GSK plc's assets grew by 2.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for GSK plc (1986–2025)
The table below shows the annual total assets of GSK plc from 1986 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | GBX61.12 Billion ≈ $7.44 Million |
+2.78% |
| 2024-12-31 | GBX59.46 Billion ≈ $7.23 Million |
+0.78% |
| 2023-12-31 | GBX59.01 Billion ≈ $7.18 Million |
-1.90% |
| 2022-12-31 | GBX60.15 Billion ≈ $7.32 Million |
-23.96% |
| 2021-12-31 | GBX79.10 Billion ≈ $9.62 Million |
-1.65% |
| 2020-12-31 | GBX80.43 Billion ≈ $9.79 Million |
+0.93% |
| 2019-12-31 | GBX79.69 Billion ≈ $9.70 Million |
+37.24% |
| 2018-12-31 | GBX58.07 Billion ≈ $7.06 Million |
+2.99% |
| 2017-12-31 | GBX56.38 Billion ≈ $6.86 Million |
-4.57% |
| 2016-12-31 | GBX59.08 Billion ≈ $7.19 Million |
+10.54% |
| 2015-12-31 | GBX53.45 Billion ≈ $6.50 Million |
+31.48% |
| 2014-12-31 | GBX40.65 Billion ≈ $4.95 Million |
-3.41% |
| 2013-12-31 | GBX42.09 Billion ≈ $5.12 Million |
+1.46% |
| 2012-12-31 | GBX41.48 Billion ≈ $5.05 Million |
+0.98% |
| 2011-12-31 | GBX41.08 Billion ≈ $5.00 Million |
-2.72% |
| 2010-12-31 | GBX42.23 Billion ≈ $5.14 Million |
-1.47% |
| 2009-12-31 | GBX42.86 Billion ≈ $5.22 Million |
+8.81% |
| 2008-12-31 | GBX39.39 Billion ≈ $4.79 Million |
+26.93% |
| 2007-12-31 | GBX31.03 Billion ≈ $3.78 Million |
+21.49% |
| 2006-12-31 | GBX25.54 Billion ≈ $3.11 Million |
-6.06% |
| 2005-12-31 | GBX27.19 Billion ≈ $3.31 Million |
+20.11% |
| 2004-12-31 | GBX22.64 Billion ≈ $2.75 Million |
-5.45% |
| 2003-12-31 | GBX23.94 Billion ≈ $2.91 Million |
+7.24% |
| 2002-12-31 | GBX22.33 Billion ≈ $2.72 Million |
+1.65% |
| 2001-12-31 | GBX21.97 Billion ≈ $2.67 Million |
+1.74% |
| 2000-12-31 | GBX21.59 Billion ≈ $2.63 Million |
+107.06% |
| 1999-12-31 | GBX10.43 Billion ≈ $1.27 Million |
+11.57% |
| 1998-12-31 | GBX9.35 Billion ≈ $1.14 Million |
+10.77% |
| 1997-12-31 | GBX8.44 Billion ≈ $1.03 Million |
+1.48% |
| 1996-12-31 | GBX8.31 Billion ≈ $1.01 Million |
-2.66% |
| 1995-12-31 | GBX8.54 Billion ≈ $1.04 Million |
+5.42% |
| 1995-06-30 | GBX8.10 Billion ≈ $985.79K |
+2.73% |
| 1994-06-30 | GBX7.89 Billion ≈ $959.62K |
+5.75% |
| 1993-06-30 | GBX7.46 Billion ≈ $907.42K |
+31.26% |
| 1992-06-30 | GBX5.68 Billion ≈ $691.34K |
-1.08% |
| 1991-06-30 | GBX5.74 Billion ≈ $698.88K |
+27.87% |
| 1990-06-30 | GBX4.49 Billion ≈ $546.55K |
+29.49% |
| 1989-06-30 | GBX3.47 Billion ≈ $422.08K |
+21.00% |
| 1988-06-30 | GBX2.87 Billion ≈ $348.83K |
+21.59% |
| 1987-06-30 | GBX2.36 Billion ≈ $286.90K |
+30.78% |
| 1986-06-30 | GBX1.80 Billion ≈ $219.37K |
-- |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more